The firms said that the kit will employ microparticle biomarker technology to identify and monitor patients at high risk of coagulation complications.
The partners aim to empower pathologists with decision support tools enabled by artificial intelligence so that patients receive a fast and accurate diagnosis.
Future Diagnostics will advise MIDS Medical about design parameters, including microfluidics and magnetic detection optimization, for a POC assay.
A microfluidic phone attachment developed at Brigham and Women's and Mass General may be the precursor of a fertility assay that men can use in the home.
The test will use plasmonics to detect DNA, microRNA, and tumor antibodies with high sensitivity within a single test.
The group has already developed a test that detects circulating tumor cells in blood and uses centrifugal microfluidics similar to the urine-based test.
A special thermal annealing process and graphene oxide structure may enable inexpensive manufacturing and use, particularly in resource-poor areas of the world.
The firm wants to develop a test that can provide objective, reliable, and rapid information so that clinicians can make critical decisions in circumstances of high uncertainty.
The initiative may lead to a test that enables clinicians to determine the presence of bacterial infections within 10 minutes.
The ASPIRE algorithm uses cell phenotype information from bone marrow samples to predict which patients will relapse and which will go into remission.